
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical Inc. is positioned for a positive financial outlook, driven by anticipated growth in the spine market and an increase in sales from enabling technologies, with adjustments indicating a potential 3% rise in revenue. The company's fourth-quarter performance showcased a robust 10% growth in Nevro, emphasizing strong core spine performance in the U.S., while organic growth is expected to improve, possibly exceeding revenue guidance. Additionally, the expectation of stabilization in EBITDA margins around 34-35% in 2026, along with strong free cash flow and strategic balance sheet management, underlines the firm's potential for operational efficiency and profitability enhancement.
Bears say
Globus Medical faces significant risks that could negatively impact its financial performance, including slower growth in the spine market and potential revenue disruptions from the mergers of NuVasive and Nevro. The bear case scenario projects revenue growth could decelerate to low single digits with flat margins, while various factors, such as competitive dynamics and underperforming product launches, pose further risks to growth. Additionally, challenges in expanding into new musculoskeletal markets and a declining capital environment for robotic purchases could adversely affect the company's operating margins and overall financial outlook.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares